StockTipsArenaBeta

SELL Dr. Reddy's Laboratories Limited — Kotak Securities

SELLDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byKotak SecuritiesHorizon: NA (inferred 1 year)26 Oct 2026via NDTV Profit

Entry₹1,260Inferred
Target₹1,220
Total upside +3.17%
Stop lossNot given
CMP₹1,310Just now
Active-3.97%+6.87%upside left 12 mo left
Follow Kotak Securities for new calls(89% target hit, 18 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 26 other Long-term calls on DRREDDYSee 132 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 27 Oct, 4:08 pm IST
12 supporting6 neutral16 opposing
Supports the SELL call (12)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·26 Oct · yesterday

5 other SEBI-registered advisors have active long-term SELL calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·26 Oct · yesterday

Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally

NewsEt-Markets·23 Oct · 3d ago

(opens in new tab)

Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates

NewsCnbc-Tv18·23 Oct · 3d ago

(opens in new tab)

Dr. Reddy's FTO-11 Facility Receives Two USFDA Form 483 Observations

NewsGoogle News·9 Oct · 3w ago

(opens in new tab)
Neutral / worth noting (6)

Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·23 Oct · 3d ago

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 1w ago

(opens in new tab)
Weighs against the SELL call (16)

2 advisors have active short-term BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·27 Oct · today

Dr Reddy's Q2 Review: Brokerages Flag Margin Recovery As Key Growth Driver — Check Target Price, Potential Upside

NewsNdtv-Profit·26 Oct · yesterday

(opens in new tab)

11 other SEBI-registered advisors have active long-term BUY calls on this stock, with 7 issued in the last 14 days

Advisor consensus · same horizon·26 Oct · yesterday

Dr Reddy's gets DGCI clearance for Zytorvi; Here's how company shares reacted

NewsCnbc-Tv18·21 Oct · 6d ago

(opens in new tab)

Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.

NSE · Press Release·21 Oct · 6d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Kotak Securities

Every call and its outcome